GlassScriptPhysician profile
Ahmad Abdin
NPI 1487060364
$16,197.50
in general payments reported to CMS, 2019-2025
30 companies · $897 in 2025
The $897 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,109 · 2020: $1,659 · 2021: $108 · 2022: $4,032 · 2023: $6,833 · 2024: $1,560 · 2025: $897.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $5,050 · Food and Beverage: $4,239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $5,049.81 |
| Food and Beverage | $4,239.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $8,108.30 | 2019-2025 | Optis, Supera, Jot Dx |
| Medtronic, INC. | $3,203.10 | 2023 | Advisa Dr Mri Surescan |
| Boston Scientific Corporation | $1,466.47 | 2019-2025 | Watchman, Lux-Dx Insertable Cardiac Monitor, Rotablator Rotational Atherectomy System Console Kit |
| Abiomed | $583.15 | 2019-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $563.48 | 2019-2025 | Lifevest |
| Amgen INC. | $389.16 | 2020-2025 | Repatha, Repatha |
| Kestra Medical Technology Services, INC. | $193.83 | 2025 | Assure Wcd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $184.67 | 2022-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $173.58 | 2021-2025 | Brilinta, Farxiga |
| Cardiovascular Systems INC. | $159.10 | 2021-2023 | Diamondback Coronary |
| E.R. Squibb & Sons, L.L.C. | $146.69 | 2024-2025 | Camzyos, Eliquis |
| Portola Pharmaceuticals, LLC | $124.59 | 2020 | |
| Merck Sharp & Dohme LLC | $119.70 | 2023-2024 | Verquvo |
| Pfizer INC. | $106.27 | 2023-2024 | |
| Philips North America LLC | $103.27 | 2025 | Azurion 7 M20 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $99.31 | 2024 | Arcalyst |
| Astellas Pharma US INC | $79.99 | 2020 | |
| Novartis Pharmaceuticals Corporation | $61.39 | 2023-2025 | |
| Stryker Corporation | $61.37 | 2025 | Flowtriever, Clottriever Bold Catheter |
| Kiniksa Pharmaceuticals, LTD. | $39.71 | 2023 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $35.86 | 2022-2023 | |
| Inari Medical, INC. | $34.47 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Abbvie INC. | $25.52 | 2021 | |
| Siemens Medical Solutions USA, INC. | $24.81 | 2023 | Artis Q Ceiling |
| Shockwave Medical, INC | $24.09 | 2022 | |
| Novo Nordisk INC | $21.97 | 2024 | Rybelsus, Ozempic |
| Ge Healthcare | $19.27 | 2025 | |
| W. L. Gore & Associates, INC. | $15.80 | 2024 | Gore Cardioform Septal Occluder |
| Bayer Healthcare Pharmaceuticals INC. | $14.74 | 2025 | |
| Janssen Pharmaceuticals, INC | $13.84 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmad Abdin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.